Clinical Trial Update: Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

The update covers a Phase 1 study of ACE-041 in patients with advanced solid tumors and relapsed/refractory multiple myeloma. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• ACE-041

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Advanced Solid Tumors, Multiple Myeloma | Phase 1 | Status: COMPLETED